NASDAQ:ADIL   Adial Pharmaceuticals, Inc
10:09 AM EDT, 09/11/2019 (MT Newswires) -- Adial Pharmaceuticals (ADIL) said Wednesday that it has successfully retested a previously manufactured supply of clinical trial packaged tablets of the investigational drug AD04 for the treatment of alcohol use disorder.

The company said tests showed that the clinical trial materials passed reevaluation and are eligible for use in the phase 3 trial.

The company has great information about it on their website with promising statisics.

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。